People at Risk for Alzheimer’s Wanted for Major Study Testing Possible Preventive Therapies

People at Risk for Alzheimer’s Wanted for Major Study Testing Possible Preventive Therapies
Older people — ages 60 to 75 — in good cognitive health but with two copies of the “risk gene” for Alzheimer’s disease (AD) are being asked to take part in Generation Study, a collaborative and global research project investigating treatments that might stop the disease from developing. Two copies of the APOE4 gene are inherited, one from each parent, and people who meet age and

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Brad Sparks says:

    If you’re serious about treating and likely preventing Alzheimer’s, as well as Parkinson’s, MS, ALS and other neurodegenerative diseases, then start supporting and funding that trial activities of Anavex Life Sciences. Its approach is more upstream, actually addressing the cause of these CNS disorders: neurodegeneration. By properly modulating Sigma-1 and Muscarinic receptors, cellular homeostasis can be restored. All patients from the Phase 2a trial have stabilized and many are better than when they began, returning to playing the piano, oil painting, golfing and simple daily living. Anavex’s Phase 2b/3 trial is about to commence and will only require 300 patients.

    Anavex’s SigmaCeptor drug platform will no doubt be the leader in a whole new generation of drugs designed to maintain cellular balance and treating/preventing a multitude of CNS disorders.

Leave a Comment

Your email address will not be published. Required fields are marked *